The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Gynecologic Cancers
A randomized phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Brian Slomovitz
View presentation
Poster
T-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01)
Antonio González-Martín
View presentation
Oral
R-DXd
ESMO 2025 | October 17-21, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: Primary analysis of the phase 2, dose-optimization part of the REJOICE-Ovarian01 study
Isabelle Ray-Coquard
View presentation
Mini-Oral
R-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) monotherapy in patients with heavily pretreated platinum-sensitive ovarian cancer: Subgroup analysis of a Phase 1 study
Kathleen Moore
View presentation
Poster
R-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
REJOICE-Ovarian02: A phase 1b/2 study of raludotatug deruxtecan (R-DXd) with other anticancer agents in participants with relapsed ovarian cancer after platinum-based chemotherapy
Ana Oaknin
View presentation
Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24